EA202190100A1 - Химерные рецепторы факторов роста - Google Patents

Химерные рецепторы факторов роста

Info

Publication number
EA202190100A1
EA202190100A1 EA202190100A EA202190100A EA202190100A1 EA 202190100 A1 EA202190100 A1 EA 202190100A1 EA 202190100 A EA202190100 A EA 202190100A EA 202190100 A EA202190100 A EA 202190100A EA 202190100 A1 EA202190100 A1 EA 202190100A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
tumor
growth factors
chimeric receptors
crgfr
Prior art date
Application number
EA202190100A
Other languages
English (en)
Russian (ru)
Inventor
Никола Кайе Прайс
Джон Стивен Бриджмен
Original Assignee
ИНСТИЛ БАЙО (ЮКей) ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63042840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202190100(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ИНСТИЛ БАЙО (ЮКей) ЛИМИТЕД filed Critical ИНСТИЛ БАЙО (ЮКей) ЛИМИТЕД
Publication of EA202190100A1 publication Critical patent/EA202190100A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EA202190100A 2018-06-21 2019-06-21 Химерные рецепторы факторов роста EA202190100A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810181.6A GB201810181D0 (en) 2018-06-21 2018-06-21 Cells expressing chimeric recominant growth factor receptors
PCT/GB2019/051745 WO2019243835A1 (en) 2018-06-21 2019-06-21 Chimeric growth factor receptors

Publications (1)

Publication Number Publication Date
EA202190100A1 true EA202190100A1 (ru) 2021-04-23

Family

ID=63042840

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190100A EA202190100A1 (ru) 2018-06-21 2019-06-21 Химерные рецепторы факторов роста

Country Status (19)

Country Link
US (1) US20210205365A1 (enExample)
EP (1) EP3810646A1 (enExample)
JP (2) JP2021527425A (enExample)
KR (1) KR20210022690A (enExample)
CN (1) CN112601759A (enExample)
AU (1) AU2019289202B2 (enExample)
BR (1) BR112020026233A2 (enExample)
CA (1) CA3104079A1 (enExample)
CL (1) CL2020003319A1 (enExample)
CO (1) CO2020016052A2 (enExample)
CR (1) CR20200624A (enExample)
EA (1) EA202190100A1 (enExample)
EC (1) ECSP20082338A (enExample)
GB (1) GB201810181D0 (enExample)
IL (1) IL279469A (enExample)
MX (1) MX2020014257A (enExample)
PH (1) PH12020500678A1 (enExample)
SG (1) SG11202012726QA (enExample)
WO (1) WO2019243835A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
WO2021173586A1 (en) * 2020-02-24 2021-09-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
EP4263807A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
CA3205464A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
EP4370139A4 (en) 2021-07-14 2025-10-15 Synthekine Inc METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE
CN122094708A (zh) * 2023-10-03 2026-05-26 美国政府(由卫生和人类服务部的部长所代表) 表达嵌合造血生长因子受体的nk细胞或t细胞及使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20011026A3 (cs) * 1998-09-23 2001-08-15 Zymogenetics, Inc. Izolovaný polynukleotid, expresní vektor, kultivovaná buňka, konstrukt DNA, způsob produkce proteinu, izolovaný polypeptid, způsob produkce protilátky, protilátka a způsob detekce
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
WO2015188141A2 (en) * 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
GB201522097D0 (en) * 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
WO2018175476A1 (en) * 2017-03-20 2018-09-27 Baylor College Of Medicine Transgenic c-mpl provides ligand-dependent co-stimulation and cytokine signals to tcr-engineered cells

Also Published As

Publication number Publication date
KR20210022690A (ko) 2021-03-03
AU2019289202B2 (en) 2024-10-31
SG11202012726QA (en) 2021-01-28
ECSP20082338A (es) 2021-02-26
US20210205365A1 (en) 2021-07-08
CO2020016052A2 (es) 2021-01-29
EP3810646A1 (en) 2021-04-28
CR20200624A (es) 2021-06-24
MX2020014257A (es) 2021-07-21
JP2021527425A (ja) 2021-10-14
CL2020003319A1 (es) 2021-07-09
BR112020026233A2 (pt) 2021-04-20
PH12020500678A1 (en) 2021-07-12
JP2024156656A (ja) 2024-11-06
AU2019289202A1 (en) 2021-01-14
GB201810181D0 (en) 2018-08-08
CA3104079A1 (en) 2019-12-26
CN112601759A (zh) 2021-04-02
WO2019243835A1 (en) 2019-12-26
IL279469A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
PH12020500678A1 (en) Chimeric growth factor receptors
Patel et al. Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer
Knorr et al. Clinical utility of natural killer cells in cancer therapy and transplantation
MX2020003945A (es) Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
Niederkorn Emerging concepts in CD8+ T regulatory cells
Bernatchez et al. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy
CN114786687A (zh) 用于过继细胞疗法的Cbl抑制剂和组合物
JP2022513131A (ja) 複数の免疫細胞タイプの同時増殖のための方法、関連する組成物および癌免疫療法におけるそれらの使用
EP3770251A1 (en) Method for producing natural killer cells
WO2008142862A1 (ja) 血管内皮前駆細胞の移植による抗がん療法
Choi et al. The past, present, and future of adoptive T cell therapy
JP2022521027A5 (enExample)
CN102154207B (zh) CD8α-白介素21-CD137复合物扩增激活淋巴细胞的方法
CN103243072B (zh) CD8α-白介素21片段-CD137复合物扩增激活淋巴细胞的方法
WO2020185056A3 (ko) 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제
KR102306231B1 (ko) 편도 유래 중간엽 줄기세포로부터 건 세포의 분화방법
US20170021002A1 (en) Augmentation of cancer and cancer endothelial vaccine immunogenicity by histone deacetylase inhibitors
Singh et al. Natural killer cell-based Immunotherapy for Solid tumors: A Comprehensive Review
WO2020037120A4 (en) Il7-il15 txm compositions and methods
Boyiadzis et al. NK cells in cancer immunotherapy: three decades of discovery
Senthil et al. The engineering of natural killer cells as an emerging adoptive cancer immunotherapy
Wu et al. 359 Leveraging tumor-trained T cells for enhanced melanoma immunotherapy
Caro-Patón Gómez Interleucinas y cáncer de colon
MX2023014084A (es) Uso de composiciones terapeuticas para el tratamiento de pacientes con tumores de origen epitelial.
Silvestre et al. Engineered CD19-CAR NK cells as an off-the-shelf alternative to B cell leukemia and lymphoma treatment